Sequella Receives $244K NIAID Grant for Drug-Resistant TB Assay | GenomeWeb
NEW YORK (GenomeWeb News) – Clinical-stage biopharmaceutical company Sequella said yesterday that it has received a $244,000 grant from the National Institute of Allergy and Infectious Diseases to develop a diagnostic assay that will use nucleic acid amplification to test for drug-resistant Mycobacterium tuberculosis.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.